Handle With Care: Sangamo Therapeutics Inc (NASDAQ: SGMO)

Currently, there are 166.79M common shares owned by the public and among those 154.22M shares have been available to trade.

Insiders at the company have transacted a total of 41 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 15 of these insider trades were purchases, accounting for 562,126 shares. Insider sales of the common stock occurred on 26 occasions, with total insider shares sold totaling 6,162,977 shares.

Invest Like Buffett: Travel Back in Time & Grab This High-Potential Stock Before It Explodes

Imagine buying Apple for $1, Amazon for $2, or Tesla for $3. Now, imagine the same opportunity with a hidden gem trading under $3 right now.

Our premium newsletter, powered by AI and expert analysis, uncovers these time-travel investment opportunities.

Invest like Buffett and profit from undervalued gems before the market catches on.

Limited-time offer: Get your first month for just $2.90 and start your journey to wealth creation.


However, the script later moved the day high at 0.8470, up 40.15%. The company’s stock has a 5-day price change of 43.75% and 144.61% over the past three months. SGMO shares are trading 48.17% year to date (YTD), with the 12-month market performance down to -73.43% lower. It has a 12-month low price of $0.29 and touched a high of $3.32 over the same period. SGMO has an average intraday trading volume of 5.34 shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 68.66%, 70.44%, and -4.80% respectively.

Institutional ownership of Sangamo Therapeutics Inc (NASDAQ: SGMO) shares accounts for 55.30% of the company’s 166.79M shares outstanding.

It has a market capitalization of $142.77M and a beta (3y monthly) value of 1.11. The earnings-per-share (ttm) stands at -$1.44. Price movements for the stock have been influenced by the stock’s volatility, which stands at 20.24% over the week and 13.80% over the month.

Analysts forecast that Sangamo Therapeutics Inc (SGMO) will achieve an EPS of $Sigma Lithium Corporation for the current quarter, $15.04 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Sagimet Biosciences Inc. – Seri while analysts give the company a high EPS estimate of $Silicon Motion Technology Corpo. Comparatively, EPS for the current quarter was $Invesco S&P 500 Momentum ETF a year ago. Earnings per share for the fiscal year are expected to decrease by -10.76%, and 65.23% over the next financial year.

Looking at the support for the SGMO, a number of firms have released research notes about the stock. RBC Capital Mkts stated their Sector Perform rating for the stock in a research note on November 03, 2023, with the firm’s price target at $6-$2.

Most Popular

Related Posts